Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tecan burnt by the Latin heat, VSM coolly strides forward in 2002

This article was originally published in Clinica

Executive Summary

Bayer's chairman, Werner Wenning, said he was not satisfied with the business trend in 2002, when the company suffered high one-off costs for acquiring Aventis CropScience, and felt the damaging effects of the high-profile Lipobay/Baycol pharmaceutical product withdrawal amid safety concerns. Although Bayer is seeking a partner for its troubled pharma division, such a tactic does not seem to be in the pipeline for diagnostics, despite the unit's sluggish sales. Diagnostics sales growth was 2% in 2002, to E2,039m ($2,168m), driven mainly by laboratory diagnostic systems and nucleic acid diagnostics. This figure represents less than 7% of total group revenues. The Ascensia Elite blood glucose monitor was Bayer Healthcare's fourth best-selling product in 2002, with sales of E515m (+5%), while the ADVIA Centaur System for large laboratories was sixth, with sales of E340m (+31%).

You may also be interested in...



California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel